| Literature DB >> 32633455 |
Dongdong Wang1, Xin Pan2, Xiaoli Wang2.
Abstract
Léri-Weill dyschondrosteosis (LWD) is usually caused by haploinsufficiency of the short stature homeobox-containing gene (SHOX). The clinical manifestation of this disease is a classic triad, which are short stature, mesomelia and Madelung deformity. LWD also includes other features, such as high body mass index. Short stature and high body mass index are risk factors of type 2 diabetes mellitus and cardiovascular disease; however, LWD combined with type 2 diabetes mellitus or metabolic syndrome have not been described in the literature. In this article, we report a case of LWD caused by an M1T mutation of the start codon of the SHOX gene. The patient also had type 2 diabetes mellitus, hypertension and dyslipidemia. It is suggested that patients with LWD should be identified promptly, and the prevention and treatment of metabolic diseases and cardiovascular disease should be taken into consideration in patients with LWD.Entities:
Keywords: Cardiovascular risk factors; Léri-Weill dyschondrosteosis; Short stature
Mesh:
Substances:
Year: 2020 PMID: 32633455 PMCID: PMC7926226 DOI: 10.1111/jdi.13350
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Figure 1Clinical characteristics and gene sequencing results of the patient and her family members. (a) The stubby forearm of the proband showing a Madelung deformity. Compared with the arm of a normal person above, the patient’s forearm shows shortness, Madelung deformity of the wrist and enlarged carrying angle. (b) The forearm roentgenogram shows the shortening and bowing of the radius. (c) Electropherogram of the SHOX gene exon 2 sequence shows the thiamine (T)>cytosine (C) transition resulting in Met1Thr mutation. (d) Pedigree of the patient’s family with SHOX gene deficiency. Males and females are indicated by squares and circles, respectively. An affected individual is indicated by filled symbols. Deceased individuals are indicated by symbols with slashes. The proband is indicated by a black arrow. The height is indicated in the lower right corner (in cm).
Laboratory investigations
| Test | Result | Normal values | ||||
|---|---|---|---|---|---|---|
| Base | 30 min after OGTT | 60 min after OGTT | 120 min after OGTT | 180 min after OGTT | ||
| PG (mmol/L) | 9.81 | 12.47 | 16.69 | 20.24 | 19.32 | – |
| INS (mIU/L) | 9 | 9.31 | 26.45 | 29.47 | 31.72 | – |
| CP (pmol/L) | 946.5 | 1434.8 | 1779 | 2233.4 | 2546.3 | – |
| HbA1c (%) | 8.6 | 4.4–6 | ||||
| LDL‐c (mmol/L) | 5.20 | 0–3.64 | ||||
| TC (mmol/L) | 7.09 | 0–5.72 | ||||
| TG (mmol/L) | 1.82 | 0–1.7 | ||||
| HDL‐c (mmol/L) | 1.00 | 0.91–1.92 | ||||
| UA (umol/L) | 290 | |||||
| TSH (mIU/L) | 0.2279 | 0.35–4.94 | ||||
| fT4 (pmol/L) | 16.38 | 9.01–19.05 | ||||
| fT3 (pmol/L) | 3.35 | 2.63–5.7 | ||||
| TRAb (IU/L) | 16.97 | 0–1.75 | ||||
| GAD (IU/mL) | 9.5 | 0–17 | ||||
| IAA (IU/mL) | 6.53 | 0.41–20 | ||||
CP, serum C‐peptide; fT3, free triiodothyronine; fT4, free thyroxine; GAD, glutamic acid decarboxylase; HbA1c, hemoglobin A1c; HDL‐c, high density lipoprotein cholesterol; IAA, insulin autoantibody; INS, serum insulin; LDL‐c, low density lipoprotein cholesterol; PG, plasma glucose; TC, total cholesterol; TG, triglyceride; TRAb, thyrotropin‐releasing hormone receptor antibody; TSH, thyrotropin‐releasing hormone; UA, uric acid.